AU2016240220B2 - Designed ankyrin repeat domains with binding specificity for serum albumin - Google Patents

Designed ankyrin repeat domains with binding specificity for serum albumin Download PDF

Info

Publication number
AU2016240220B2
AU2016240220B2 AU2016240220A AU2016240220A AU2016240220B2 AU 2016240220 B2 AU2016240220 B2 AU 2016240220B2 AU 2016240220 A AU2016240220 A AU 2016240220A AU 2016240220 A AU2016240220 A AU 2016240220A AU 2016240220 B2 AU2016240220 B2 AU 2016240220B2
Authority
AU
Australia
Prior art keywords
ankyrin repeat
designed ankyrin
binding specificity
serum albumin
repeat domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016240220A
Other languages
English (en)
Other versions
AU2016240220A1 (en
Inventor
Johan ABRAM SALIBA
Talitha BAKKER
Hans Kaspar Binz
Ignacio DOLADO
Patrik Forrer
Maya Gulotti-Georgieva
Frieder W. Merz
Douglas Phillips
Ivo Sonderegger
Daniel Steiner
Michael T. Stumpp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Partners AG
Original Assignee
Molecular Partners AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners AG filed Critical Molecular Partners AG
Publication of AU2016240220A1 publication Critical patent/AU2016240220A1/en
Application granted granted Critical
Publication of AU2016240220B2 publication Critical patent/AU2016240220B2/en
Priority to AU2020201264A priority Critical patent/AU2020201264A1/en
Priority to AU2021286418A priority patent/AU2021286418B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
AU2016240220A 2015-04-02 2016-04-01 Designed ankyrin repeat domains with binding specificity for serum albumin Ceased AU2016240220B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020201264A AU2020201264A1 (en) 2015-04-02 2020-02-21 Designed ankyrin repeat domains with binding specificity for serum albumin
AU2021286418A AU2021286418B2 (en) 2015-04-02 2021-12-17 Designed ankyrin repeat domains with binding specificity for serum albumin

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15162502 2015-04-02
EP15162511 2015-04-02
EP15162511.8 2015-04-02
EP15162502.7 2015-04-02
PCT/EP2016/057272 WO2016156596A1 (en) 2015-04-02 2016-04-01 Designed ankyrin repeat domains with binding specificity for serum albumin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020201264A Division AU2020201264A1 (en) 2015-04-02 2020-02-21 Designed ankyrin repeat domains with binding specificity for serum albumin

Publications (2)

Publication Number Publication Date
AU2016240220A1 AU2016240220A1 (en) 2017-10-19
AU2016240220B2 true AU2016240220B2 (en) 2019-11-21

Family

ID=55650423

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016240220A Ceased AU2016240220B2 (en) 2015-04-02 2016-04-01 Designed ankyrin repeat domains with binding specificity for serum albumin
AU2020201264A Abandoned AU2020201264A1 (en) 2015-04-02 2020-02-21 Designed ankyrin repeat domains with binding specificity for serum albumin
AU2021286418A Active AU2021286418B2 (en) 2015-04-02 2021-12-17 Designed ankyrin repeat domains with binding specificity for serum albumin

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020201264A Abandoned AU2020201264A1 (en) 2015-04-02 2020-02-21 Designed ankyrin repeat domains with binding specificity for serum albumin
AU2021286418A Active AU2021286418B2 (en) 2015-04-02 2021-12-17 Designed ankyrin repeat domains with binding specificity for serum albumin

Country Status (20)

Country Link
US (3) US9458211B1 (cg-RX-API-DMAC7.html)
EP (2) EP4272838A3 (cg-RX-API-DMAC7.html)
JP (1) JP6552636B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220109488A (cg-RX-API-DMAC7.html)
CN (1) CN107454904A (cg-RX-API-DMAC7.html)
AU (3) AU2016240220B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017020986A2 (cg-RX-API-DMAC7.html)
CA (1) CA2979602C (cg-RX-API-DMAC7.html)
CL (1) CL2017002454A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017009954A2 (cg-RX-API-DMAC7.html)
ES (1) ES2953482T3 (cg-RX-API-DMAC7.html)
IL (2) IL276944B (cg-RX-API-DMAC7.html)
MX (2) MX2022008302A (cg-RX-API-DMAC7.html)
MY (1) MY179505A (cg-RX-API-DMAC7.html)
NZ (1) NZ735803A (cg-RX-API-DMAC7.html)
PH (1) PH12017501792B1 (cg-RX-API-DMAC7.html)
RU (1) RU2769470C2 (cg-RX-API-DMAC7.html)
SA (1) SA517390092B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201707606RA (cg-RX-API-DMAC7.html)
WO (1) WO2016156596A1 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
DK2643349T3 (da) * 2010-11-26 2019-11-25 Molecular Partners Ag Designede repeat-proteiner, der binder til serumalbumin
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
SG11201900464TA (en) 2016-07-20 2019-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
MX377424B (es) * 2016-09-22 2025-03-10 Molecular Partners Ag Proteinas de union recombinantes y sus usos
CN110959015B (zh) * 2017-07-12 2023-07-25 四川科伦博泰生物医药股份有限公司 双特异性重组蛋白
SG11202001420VA (en) * 2017-08-18 2020-03-30 Cambridge Entpr Ltd Modular binding proteins
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
EP3941580A1 (en) * 2019-03-22 2022-01-26 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf
EP3980452A1 (en) 2019-06-04 2022-04-13 Molecular Partners AG Recombinant 4-1bb binding proteins and their use
EP3980443A1 (en) * 2019-06-04 2022-04-13 Molecular Partners AG Multispecific proteins
CN114206908B (zh) * 2019-06-04 2025-12-23 分子伴侣公司 具有改善的稳定性的经设计的锚蛋白重复结构域
CA3139164A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use
WO2021116462A1 (en) * 2019-12-11 2021-06-17 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
JP2023506763A (ja) 2019-12-11 2023-02-20 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えペプチド－ｍｈｃ複合体結合タンパク質並びにそれらの生成及び使用
TW202208404A (zh) * 2020-05-06 2022-03-01 瑞士商分子組合公司 新穎錨蛋白重複結合蛋白質及其用途
US20240279309A1 (en) * 2020-05-14 2024-08-22 Molecular Partners Ag Recombinant cd40 binding proteins and their use
CN115768786A (zh) 2020-05-14 2023-03-07 分子合作伙伴股份公司 多特异性蛋白质
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
CA3202358A1 (en) * 2020-12-16 2022-06-23 Andreas BOSSHART Novel slow-release prodrugs
EP4263608A1 (en) 2020-12-16 2023-10-25 Molecular Partners AG Recombinant cd3 binding proteins and their use
JP2024509904A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ
US20240150475A1 (en) 2021-03-09 2024-05-09 Molecular Partners Ag Novel darpin based cd123 engagers
CA3211248A1 (en) 2021-03-09 2022-09-15 Nina RESCHKE Novel darpin based cd33 engagers
WO2022190008A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Protease cleavable prodrugs
AU2022413461A1 (en) 2021-12-14 2024-06-06 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
CN114957426B (zh) * 2022-06-02 2023-05-16 华南师范大学 Sp6rars及其在防治蜚蠊目昆虫中的应用
CN119731200A (zh) 2022-08-01 2025-03-28 分子合作伙伴股份公司 经电荷修饰设计的重复结构域及其用途
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
WO2024251628A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
WO2024251742A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd2 binding proteins and their use
WO2024251695A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd47 binding proteins and their use
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025146487A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Multispecific binding proteins
WO2025146490A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Recombinant cd117 binding proteins and their use
WO2025163144A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use
US20250332297A1 (en) 2024-01-31 2025-10-30 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060748A1 (en) * 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
WO2012069654A1 (en) * 2010-11-26 2012-05-31 Molecular Partners Ag Designed repeat proteins binding to serum albumin
WO2012069557A1 (en) * 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
WO2014191574A1 (en) * 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
ES2335861T3 (es) 2000-09-08 2010-04-06 Universitat Zurich Grupos de proteinas repetitivas que comprenden modulos repetitivos.
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
AU2005303912B2 (en) 2004-11-12 2011-02-17 Bayer Schering Pharma Aktiengesellschaft Recombinant Newcastle Disease Virus
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
WO2007006665A1 (en) 2005-07-08 2007-01-18 University Of Zürich Phage display using cotranslational translocation of fusion polypeptides
AU2007223888A1 (en) 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
WO2009040338A1 (en) 2007-09-24 2009-04-02 University Of Zürich Designed armadillo repeat proteins
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CN110437320B (zh) * 2010-07-09 2023-10-20 阿菲博迪公司 多肽
AU2011281702A1 (en) * 2010-07-19 2013-01-31 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
EP2702069A4 (en) 2011-04-29 2015-04-29 Janssen Biotech Inc IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF
EP2867360B1 (en) 2012-06-28 2019-05-08 Molecular Partners AG Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) * 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060748A1 (en) * 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
WO2012069557A1 (en) * 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
WO2012069654A1 (en) * 2010-11-26 2012-05-31 Molecular Partners Ag Designed repeat proteins binding to serum albumin
WO2014191574A1 (en) * 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ulrike Fiedler, et al., "Antitumor activity of MP0250, a bispecific VEGF- and HGF-targeting darpin, in patient-derived xenograft models.", J Clin Oncol (2014)32:5s, 2014 (suppl; abstr 11039) *

Also Published As

Publication number Publication date
CA2979602C (en) 2022-12-20
MX393655B (es) 2025-03-24
EP3277711B1 (en) 2023-06-07
EP4272838A2 (en) 2023-11-08
US20160362453A1 (en) 2016-12-15
SA517390092B1 (ar) 2022-03-03
IL254788A0 (en) 2017-12-31
AU2021286418A1 (en) 2022-01-20
EP3277711A1 (en) 2018-02-07
AU2016240220A1 (en) 2017-10-19
EP3277711C0 (en) 2023-06-07
JP2018511327A (ja) 2018-04-26
AU2021286418B2 (en) 2024-01-04
US11332501B2 (en) 2022-05-17
KR20170131515A (ko) 2017-11-29
AU2020201264A1 (en) 2020-03-12
ES2953482T3 (es) 2023-11-13
RU2017134456A (ru) 2019-04-03
EP3277711B9 (en) 2023-08-16
RU2769470C2 (ru) 2022-04-01
PH12017501792B1 (en) 2022-07-20
KR20220109488A (ko) 2022-08-04
MX2017012485A (es) 2018-04-11
MY179505A (en) 2020-11-09
RU2017134456A3 (cg-RX-API-DMAC7.html) 2019-10-08
BR112017020986A2 (pt) 2018-08-14
SG11201707606RA (en) 2017-10-30
IL254788B (en) 2020-09-30
CL2017002454A1 (es) 2018-05-25
US20190263869A1 (en) 2019-08-29
IL276944B (en) 2022-07-01
NZ735803A (en) 2021-12-24
US20160289285A1 (en) 2016-10-06
CO2017009954A2 (es) 2018-02-20
US9458211B1 (en) 2016-10-04
MX2022008302A (es) 2023-02-28
IL276944A (en) 2020-10-29
PH12017501792A1 (en) 2019-01-21
JP6552636B2 (ja) 2019-07-31
CA2979602A1 (en) 2016-10-06
HK1244009A1 (en) 2018-07-27
CN107454904A (zh) 2017-12-08
US10155791B2 (en) 2018-12-18
WO2016156596A1 (en) 2016-10-06
KR102427117B1 (ko) 2022-07-29
EP4272838A3 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
PH12019500596B1 (en) Recombinant binding proteins and their use
EA201892691A1 (ru) Однодоменный белок, связывающий сывороточный альбумин
MX2024005946A (es) Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.
BR112017015567A2 (pt) proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
HK1258509A1 (zh) Gitr激动剂
GEP20227447B (en) Constructs having sirp-alpha domain or variant thereof
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
WO2015109124A3 (en) Immunomodulatory agents
NZ748307A (en) Gdf15 fusion proteins and uses thereof
MX2022013945A (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos.
EA201491644A1 (ru) Фармацевтические композиции
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
AU2016229053A8 (en) Fusion protein comprising a ligand binding domain of VEGF and PDGF
AU2018277310A1 (en) Aggrecan binding immunoglobulins
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2020009550A (es) Proteinas de union a antigeno antagonistas.
ZA202403355B (en) Single domain antibodies binding to tetanus neurotoxin
BR112017000710A2 (pt) polipeptídeo isolado, polipeptídeo modificado de revestimento final isolado, composição de matéria, polipeptídeo de fusão isolado, composição farmacêutica, método de tratamento de uma doença inflamatória, uso do polipeptídeo isolado, polinucleotídeo isolado, estrutura de ácido nucleico, e método de determinação da potência de um lote do polipeptídeo isolado
EP3956350C0 (en) MODIFIED CRY PROTEINS FOR DELIVERY OF THERAPEUTIC AGENTS
NZ727444A (en) Prohemostatic proteins for the treatment of bleeding
CA3009928A1 (en) Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired